Progressive familial intrahepatic cholestasis (PFIC) is a progressive disorder that affects children. It is initially characterized by intrahepatic cholestasis which worsens over time. It may present with jaundice in the first weeks of life, or may appear after several months. Byler’s disease, another term for one type of PFIC, was coined after an immigrant who brought the disorder to the USA. PFIC is a rare inherited disorder in which at least three subtypes have been identified, and called PFIC-1, PFIC-2, and PFIC-3. These three subtypes carry descriptive names which partially describe them: PFIC-1 is called familial intrahepatic cholestasis, PFIC-2 may be called bile salt export pump deficiency, and PFIC-3 is multidrug resistant-associated protein deficiency. A mild not as severe form of PFIC is called benign recurrent intrahepatic cholestasis.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Ahboucha, S., and Butterworth, R. (2007) The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy. Metab. Brain Dis. 22:291–308PubMedCrossRefGoogle Scholar
Anderson, G. (2004) Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 63:S24–S29CrossRefGoogle Scholar
Balistreri, W. (1997) Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastro. Nutrit. 24:573–589CrossRefGoogle Scholar
Belanger, M., and Butterworth, R. (2005) Acute liver failure: A critical appraisal of available animal models. Met. Brain Dis. 20:409–424CrossRefGoogle Scholar
Cauli, O., et al. (2005) Altered modulation of motor activity by group 1 metabotropic glutamate receptors in the nucleus accumbens in hyperammonemic rats. Metab. Brain Dis. 20:347–358PubMedCrossRefGoogle Scholar
Schenker, S., et al. (1967) Studies on the intracerebral toxicity of ammonia. J. Clin. Med. 46:838–848Google Scholar
Shet, R. (2004) Metabolic concerns associated with antiepileptic medications. Neurology 63:24–29CrossRefGoogle Scholar
Shigematsu, Y., et al. (2002) Newborn mass screening and selective screening using electrospray tandem mass spectrometry in Japan. J. Chrom B Analyt. Tech. Biomed. Life Sci. 776:39–48CrossRefGoogle Scholar
Smetana, H., Edlow, J., and Glunz, P. (1965) Neonatal jaundice. Arch. Path. 80:553–574PubMedGoogle Scholar
Soylu, A., et al. (2008) Intrahepatic cholestasis in subclinical and overt hyperthyroidism: two case reports. J. Med. Case Rep. 2:116–123PubMedCrossRefGoogle Scholar
van Nievwkerk, C., et al. (1996) Progressive familial intrahepatic cholestasis Gastroent 111:165–171CrossRefGoogle Scholar
Wang, X., and Anderson, R. (1994) Hepatocyte transplantation : a potential treatment for acute liver failure. Scand. J. Gastroent. 30:193–200CrossRefGoogle Scholar
WHO Severe and complicated malaria: A report of the WHO malaria action programme. Trans. R. Soc. Med. Hyg. 80:1–50Google Scholar
Wright, G., et al. (2007) Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab. Brain Dis. 22:375–388PubMedCrossRefGoogle Scholar
Rose, C., and Felipo, V. (2005) Limited capacity for ammonia removal by brain in chronic liver failure: potential role of nitric oxide. Metab. Brain Dis. 20:275–284PubMedCrossRefGoogle Scholar
Tobias, J. (2002) Ursodeoxycholic acid in the treatment of cholestasis and hyperbilirubinemia in pediatric intensive care unit patients. South. Med. J. online Nov 1, 2002, a09723387Google Scholar
Bhatia, V., Batra, Y., and Acharya, S. (2004) Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure-a controled clinical trial. J. Hepatol. 41:89–96PubMedCrossRefGoogle Scholar